← Leaderboards
Renzhi Han
Loyola University Chicago
$10,497,939
Attributed
$12,619,430
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,619,430 · 7
By mechanism
R01$12,183,555 · 6
R21$435,875 · 1
Top collaborators
- Yuqing E Chen6 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoAnimal ModelCellsMediatingGenesDesignHuman DiseaseProteinsMuscular DystrophiesLipidsRepairedMutationMuscleExperimental StudyLightGeneticMouse ModelMutantKnockout MiceMolecularMembraneResponseOryctolagus CuniculusInsight
Grant awards (29)
Targeted editing of ASGR1 for cardiovascular diseases$707,525
R01 · FY2025 · HL · contact PI
Controllable base editing therapy for DMD$599,523
R01 · FY2025 · HL · contact PI
Targeted editing of ASGR1 for cardiovascular diseases$722,150
R01 · FY2024 · HL · contact PI
Development of gene editing based therapy for cardiovascular diseases$689,276
R01 · FY2024 · HL
Controllable base editing therapy for DMD$587,533
R01 · FY2024 · HL · contact PI
Base editing of ASGR1 for cardiovascular disease$237,750
R21 · FY2024 · HL · contact PI
Development of gene editing based therapy for cardiovascular diseases$703,344
R01 · FY2023 · HL
Controllable base editing therapy for DMD$599,523
R01 · FY2023 · HL · contact PI
Base editing of ASGR1 for cardiovascular disease$198,125
R21 · FY2023 · HL · contact PI
Development of gene editing based therapy for cardiovascular diseases$703,344
R01 · FY2022 · HL
ANO5 in Muscle Health and Disease$383,637
R01 · FY2022 · HL · contact PI
ANO5 in Muscle Health and Disease$225,340
R01 · FY2022 · HL · contact PI
Development of gene editing based therapy for cardiovascular diseases$717,344
R01 · FY2021 · HL
ANO5 in Muscle Health and Disease$616,947
R01 · FY2021 · HL · contact PI
Myokine function of MG53 in muscle injury-repair and regeneration$342,103
R01 · FY2021 · AR · contact PI
ANO5 in Muscle Health and Disease$624,760
R01 · FY2020 · HL · contact PI
ANO5 in Muscle Health and Disease$632,422
R01 · FY2019 · HL · contact PI
Molecular and cellular functions of Ano5 in heart$385,000
R01 · FY2017 · HL · contact PI
Mechanisms of Muscle Inflammation in Muscular Dystrophy$269,493
R01 · FY2017 · AR · contact PI
Molecular and cellular functions of Ano5 in heart$385,000
R01 · FY2016 · HL · contact PI
Mechanisms of Muscle Inflammation in Muscular Dystrophy$269,493
R01 · FY2016 · AR · contact PI
Molecular and cellular functions of Ano5 in heart$379,225
R01 · FY2015 · HL · contact PI
Mechanisms of Muscle Inflammation in Muscular Dystrophy$269,493
R01 · FY2015 · AR · contact PI
Molecular and cellular functions of Ano5 in heart$328,244
R01 · FY2014 · HL · contact PI
Mechanisms of Muscle Inflammation in Muscular Dystrophy$267,086
R01 · FY2014 · AR · contact PI
Mechanisms of Muscle Inflammation in Muscular Dystrophy$53,789
R01 · FY2014 · AR · contact PI
Molecular and cellular functions of Ano5 in heart$41,706
R01 · FY2014 · HL · contact PI
Molecular and cellular functions of Ano5 in heart$359,380
R01 · FY2013 · HL · contact PI
Mechanisms of Muscle Inflammation in Muscular Dystrophy$320,875
R01 · FY2013 · AR · contact PI